Rapid viral suppression using integrase inhibitors during acute HIV-1 infection
Author Information
Author(s): McKellar Mehri S, Keys Jessica R, Filiatreau Lindsey M, McGee Kara S, Kuruc Joann D, Ferrari Guido, Margolis David M, Eron Joseph J, Hicks Charles B, Gay Cynthia L
Primary Institution: Duke University and University of North Carolina at Chapel Hill
Hypothesis
Does integrase inhibitor-based therapy lead to faster viral suppression in acute HIV-1 infection compared to non-nucleoside reverse transcriptase inhibitor-based therapy?
Conclusion
INSTI-based ART during AHI resulted in rapid and sustained viral suppression.
Supporting Evidence
- 100% of participants in the INSTI cohort achieved HIV-1 RNA <200 copies/mL by Week 24.
- Time to viral suppression was shorter in the INSTI cohort (median 54 days) compared to the NNRTI cohort (99 days).
- Weight gain was similar between the INSTI and NNRTI cohorts over 96 weeks.
Takeaway
This study shows that a specific HIV treatment can help people get better faster when they first get the virus.
Methodology
A single arm, 96-week study of a once-daily integrase inhibitor-based regimen in participants with acute HIV-1 infection.
Limitations
The study had a relatively small sample size.
Participant Demographics
Most participants were African American (61%) and men who have sex with men (73%), with a median age of 26 years.
Statistical Information
P-Value
<0.01
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website